Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,544 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Girls, alone Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

User Testing of the Evivo Screening Test

NCT03601936
View directory record Official record
Conditions
Gut Microbiome
Interventions
Evivo Infant Gut Bifidobacterium Screening Test
Device
Lead sponsor
Evolve BioSystems, Inc.
Industry
Eligibility
Up to 6 Months
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Marietta, Georgia • Gresham, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

NCT03159702
View directory record Official record
Conditions
Hematological Malignancy, Multiple Myeloma
Interventions
Evomela, Fludarabine, Total Body Irradiation, Haploidentical Hematopoietic Cell Transplantation
Drug · Radiation · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Not applicable Interventional Results available

Mindfulness Meditation for the Treatment of Women With Comorbid PTSD and SUD

NCT02755103
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Substance-Related Disorders
Interventions
Mindfulness Based Relapse Prevention (MBRP)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm

NCT00964730
View directory record Official record
Conditions
Healthy
Interventions
Talampanel, Moxifloxacin, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2010 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers

NCT01303445
View directory record Official record
Conditions
Healthy
Interventions
Aggrenox alone, Aggrenox and omeprazole, Omeprazole alone
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

NCT03674177
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prevention of GBS Colonization Via Immunity

NCT00128219
View directory record Official record
Conditions
Beta Haemolytic Streptococcal Infection
Interventions
GBS III-TT, Tetanus and diptheria toxoids vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
3
States / cities
Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 28, 2026, 12:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Trans-MAPP Symptom Patterns Study (SPS)

NCT02514265
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Prostatitis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Educating Women About Pelvic Floor Disorders During Pregnancy

NCT05440539
View directory record Official record
Conditions
Pelvic Floor Disorders, Stress Urinary Incontinence, Pelvic Organ Prolapse
Interventions
Written Handouts, Interactive Workshop
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

NCT05505162
View directory record Official record
Conditions
Healthy Female Participants
Interventions
Zibotentan, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Not applicable Interventional Results available

MyNewOptions: An Online Study of Reproductive Life Planning and Contraceptive Action Planning

NCT02100124
View directory record Official record
Conditions
Contraceptive Use, Unintended Pregnancy
Interventions
Reproductive Life Planning (RLP), Contraceptive Action Planning, Contraception information
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 28, 2026, 12:05 AM EDT
Recruiting Not applicable Interventional

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women

NCT07209397
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant), Mixed Urinary Incontinence, Idiopathic Overactive Bladder With Urinary Incontinence, Idiopathic Overactive Bladder
Interventions
Detrusor nerve radiofrequency ablation, Simulated (sham) detrusor nerve radiofrequency ablation
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
22 Years to 80 Years · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Women's Health Habits Study

NCT00846638
View directory record Official record
Conditions
Risk Drinking,Diabetes, Hypertension, Osteoporosis, Infertility
Interventions
Brief Intervention, Diagnostic assessment
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2010 · Synced Oct 28, 2026, 12:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

DXA Study of Precision and Reliability

NCT03621306
View directory record Official record
Conditions
Bone and Bones, Body Composition
Interventions
DXA and pQCT precision testing
Device
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2028
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 3 Interventional Results available

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin
Drug · Other · Procedure + 1 more
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 65 Years · Female only
Enrollment
3,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
480
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Not applicable Interventional

Feasibility Study of the AblaCare System in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With Infertility Due to Polycystic Ovary Syndrome

NCT05320289
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility, Female
Interventions
AblaCare System
Device
Lead sponsor
May Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 28, 2026, 12:05 AM EDT
Recruiting No phase listed Observational

A Study of Prucalopride in Breastfeeding Women With Constipation

NCT04838522
View directory record Official record
Conditions
Chronic Idiopathic Constipation (CIC)
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stress & Premenstrual Symptoms Study

NCT02777372
View directory record Official record
Conditions
PMDD, Stress, Mood
Interventions
Sertraline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 28, 2026, 12:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Respiratory Load Magnitude Estimation in PD

NCT02202057
View directory record Official record
Conditions
Parkinson's Disease, Aging
Interventions
Respiratory resistive load on inhalation, Fluoroscopic swallowing evaluation
Other
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.

NCT00416728
View directory record Official record
Conditions
Healthy
Interventions
Aliskiren, Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 22, 2007 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

NCT00524303
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Trastuzumab, Paclitaxel, FEC75, Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
23
States / cities
Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

NCT00835861
View directory record Official record
Conditions
Non Insulin Dependent Diabetes, Pregnancy
Interventions
Metformin, Insulin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects

NCT01114152
View directory record Official record
Conditions
Healthy
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 28, 2026, 12:05 AM EDT
Completed Phase 1 Interventional

Raltegravir as Early Therapy in African-Americans Living With HIV Study

NCT00667433
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir + Truvada
Drug
Lead sponsor
David A Wohl, MD
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 28, 2026, 12:05 AM EDT